Natural History of Tuberculosis: Duration and Fatality of Untreated Pulmonary Tuberculosis in HIV Negative Patients: A Systematic Review
Open accessThe DOI matches its Crossref record; 136 of the 136 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The prognosis, specifically the case fatality and duration, of untreated tuberculosis is important as many patients are not correctly diagnosed and therefore receive inadequate or no treatment. Furthermore, duration and case fatality of tuberculosis are key parameters in interpreting epidemiological data. METHODOLOGY AND PRINCIPAL FINDINGS: To estimate the duration and case fatality of untreated pulmonary tuberculosis in HIV negative patients we reviewed studies from the pre-chemotherapy era. Untreated smear-positive tuberculosis among HIV negative individuals has a 10-year case fatality variously reported between 53% and 86%, with a weighted mean of 70%. Ten-year case fatality of culture-positive smear-negative tuberculosis was nowhere reported directly but can be indirectly estimated to be approximately 20%. The duration of tuberculosis from onset to cure or death is approximately 3 years and appears to be similar for smear-positive and smear-negative tuberculosis. CONCLUSIONS: Current models of untreated tuberculosis that assume a total duration of 2 years until self-cure or death underestimate the duration of disease by about one year, but their case fatality estimates of 70% for smear-positive and 20% for culture-positive smear-negative tuberculosis appear to be satisfactory.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Selection of papers. Flowchart schematically showing inclusion and exclusion of papers. Those marked with a * were excluded either because they were referred to at places in the text that did not discuss duration of tuberculosis, tuberculosis mortality, case fatality, life tables or natural history, or because the title indicated that the paper was not about one of these topics; ** for two of these, data were included to the extent mentioned by Berg [115] (see legend of Table 3).](https://figures.cochat.ai/paper-figures/8114c3bf70fd484d9fe91b2b4854751c/natural-history-of-tuberculosis-duration-and-fatality-of-untreated-pulmonary-figure-1.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the average duration until cure or death is 3 years for untreated patients with tuberculosis,25”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Growing Burden of Tuberculosis: Global Trends and Interactions With the HIV Epidemic
Corbett, E. L., Watt, C. J., Walker, N., Maher, D., Williams, B. G., Raviglione, M. C., & Dye, C. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.9.1009 · Cited by 2,553 · cited 2×
“a 70% CF, as used by WHO and others in their estimates of the burden of tuberculosis [27], seems a reasonable ballpark figure.”
BackgroundMethodSelf-citationTuberculosis and diabetes mellitus: convergence of two epidemics
Dooley, K. E., & Chaisson, R. E. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70282-8 · Cited by 932 · cited 1×
“tuberculosis and progression to tuberculosis disease is influenced by host factors and especially risk of progression depends on the hosts’ immune status, which may be reduced due to concomitant HIV infection, diabetes, and other underlying diseases [27,28].”
BackgroundFluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review
Steingart, K. R., Henry, M., Ng, V., Hopewell, P. C., Ramsay, A., Cunningham, J., Urbanczik, R., Perkins, M., Aziz, M. A., & Pai, M. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70578-3 · Cited by 798 · cited 1×
“smear, with low sensitivity for paucibacillary disease, is the only available diagnostic tool [6].”
BackgroundThe Competitive Cost of Antibiotic Resistance in Mycobacterium tuberculosis
Gagneux, S., Long, C. D., Small, P. M., Van, T., Schoolnik, G. K., & Bohannan, B. J. M. (2006) · Science · doi:10.1126/science.1124410 · Cited by 627 · cited 1×
“Furthermore, Mycobacterium tuberculosis strains resistant to rifampicin and INH might be less fit than drug susceptible strains and therefore lead to longer duration of disease with less mortality [15].”
BackgroundDye, C. (2005) · JAMA · doi:10.1001/jama.293.22.2767 · Cited by 534 · cited 1×
“course) strategy only offer free treatment to smear-positive cases in view of their disproportionate role in tuberculosis transmission and thus their large public health impact [7].”
BackgroundEspinal, M. A., Kim, S. J., Suarez, P. G., Kam, K. M., Khomenko, A. G., Migliori, G. B., Baéz, J., Kochi, A., Dye, C., & Raviglione, M. C. (2000) · JAMA · doi:10.1001/jama.283.19.2537 · Cited by 507 · cited 1×
“The prognosis of untreated tuberculosis is difficult to study these days as leaving patients untreated, especially in a study setting, is unethical. As an alternative, one could consider, as an approximation, the prognosis of multi-drug resistant (MDR) tuberculosis treated with first line drugs. However, MDR-tuberculo…”
HIV Infection and Multidrug‐Resistant Tuberculosis—The Perfect Storm
Wells, C. D., Cegielski, J. P., Nelson, L. J., Laserson, K. F., Holtz, T. H., Finlay, A., Castro, K. G., & Weyer, K. (2007) · The Journal of Infectious Diseases · doi:10.1086/518665 · Cited by 483 · cited 4×
“As regards CF, the review of Payne and Bellamy [143] provided no information on the prognosis of HIV positive MDR-tuberculosis patients.”
BackgroundInfluentialTreatment of Tuberculosis in Patients with Advanced Human Immunodeficiency Virus Infection
Small, P. M., Schecter, G. F., Goodman, P. C., Sande, M. A., Chaisson, R. E., & Hopewell, P. C. (1991) · New England Journal of Medicine · doi:10.1056/nejm199101313240503 · Cited by 477 · cited 1×
“tuberculosis, of 16 months [145].”
The White Plague: Tuberculosis, Man and Society
(1954) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1954.tb85837.x · Cited by 388
Recurrence in tuberculosis: relapse or reinfection?
Lambert, M.-L., Hasker, E., Deun, A. V., Roberfroid, D., Boelaert, M., & Van der Stuyft, P. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00607-8 · Cited by 225 · cited 1×
“Moreover, of the two possible end points, cure is hard to measure, as relapses are common [140] and establishing cure in untreated tuberculosis patients requires extensive medical investigations.”
Background
Research works printed but not linked: 25
- JA Rutledge, 1919, The ultimate results in 1654 cases of tuberculosis treated at the modern Woodmen of America sanatorium., Am Rev Tuberc, 2, 755
- E Loewenstein, 1931, Die Zuchtung der Tuberkelbazillen aus dem stroemenden Blute., Zentralbl Bakteriol Parasitenkd Infektionskr Hyg, 1, 127
- KA Jensen, 1932, Reinzuchtung und Typenbestimmung von Tuberkelbazillenstammen., Zentralb Bakteriol Parasitenkd Infektionskr Hyg Abt, 1, 222
- GH Hamel, 1928, Jahresversammlung des Deutschen Zentral-komitees zur Bekämpfung der Tuberkulose. Erster Verhandlungstag. (discussions during annual meeting of the German Tuberculosis Control Committee)., Zeitschr Tuberk, 51, 497
- B Meidell, 1931, Die wahrscheinliche Lebensdauer und die Sterblichkeitsmessung., Skandinavisk aktuarietidskrift, 14, 217
- Anonymous, 1936, The expectation of life of the tuberculous., Tubercle, 17, 171
- F Oldenburg, 1931, Gedanken über das Schicksal offentuberkulöser Eisenbahner auf Grund statistischer Erhebungen., Zeitschr Tuberk, 61, 334
- S Phillips, 1964, Relapse in treated cases of pulmonary tuberculosis. II. Six-year follow-up of 109 patients discharged from the hospital with medical approval, 1955-1956., Am Rev Respir Dis, 90, 61
- W May, 1928, Welche Konsequenzen ergeben sich aus der Dauerstatistik der Heilverfahren bei Offentuberkulösen?, Zeitschr Tuberk, 51, 177
- H Ruge, 1909, Dauererfolge nach 10 Jahren bei Lungetuberkulose im Hochgebirge., Zeitsch Tuberk, 15, 146
- E Saegler, 1934, Beitrag zur Frage der Beziehungen zwischen Tuberkulose und Lebensalter., Zeitschr Tuberk, 71, 285
- E Stadler, 1903, Der Einfluss der Lungetuberkulose of Lebensdauer und Erwerbsfähigkeit und der Werth der Volksheilstättenbehandlung., Deutsch Arch Klin Med, 95, 412
- MG Stephens, 1941, Follow-up of 1041 tuberculous patients., Am Rev Tuberc, 44, 451
- PF Holst, 1906, Untersuchungen über die Lebensdauer der Schwindsüchtigen in Norwegen., Deutsch Arch Klin Med, 88, 325
- H Braeuning, 1920, Tuberkulöse Erkrankungen bei Schwestern infolge von Ansteckung im Dienst und ihre Verhütung., Zeitschr Tuberk, 33, 129
- AD De Besche, 1925, Dødeligheten av Lungentuberkulose i Oslo blandt til Byen indflyttede og der fødte Individer., Norsk Magazin for Laegevidenskaben, 86, 1229
- CRNF Van Joost, 1935, Opmerkingen naar aanleiding van een 200 tal met kunstmatige pneumothorax- en een 50 tal met middenrifsverlamming (phrenicusexairesis) behandelde gevallen van longtuberculose., Geneeskund Tijdschr v Ned Indië, 75, 1223
- B Van Vliet, 1963, Analyse van de sterfte aan longtuberculose te Amsterdam in de jaren 1960 en 1961., Ned Tijdschr Geneesk, 107, 2180
- SP Pamra, 1973, Changes in prevalence and incidence of pulmonary tuberculosis in Delhi in recent years., Ind J Tuberc, 20, 57
- CMF Sinding-Larsen, 1937, On the collapse treatment of pulmonary tuberculosis. A clinical adaption and follow-up examination of the material from Vejlefjord Sanatorium, 1906-1932., Acta Med Scand, 91, 39
- S Magnusson, 1938, Über den Verlauf und die Letalität der Tuberkulose in den verschiedenen Altersperioden., Acta Tuberc Scand, 12, 201
- W Münchbach, 1933, Das Schicksal des lungentuberkulösen Erwachsenen. Ergibnisse der Heilstattenbehandlung von annähernd 10000 Männern und Frauen., Tuberkulose-Bibliothek, 49, 64
- H Braeuning, 1936, Prognose der offenen Tuberkulose, Technik der Prognose-stellung und Rentabilität des Heilverfahrens., Zeitschr Tuberk, 75, 305
- H Braeuning, 1933, Die Prognose der offenen Lungentuberkulose., Tuberkulose-Bibliothek, 52, 40
- H Braeuning, 1930, Über die Letalität, Morbidität und Infektionsdauer der offenen Lungentuberkulose., Zeitschr Tuberk, 59, 109
Cited by
Items 401–500 of 630
George, M., Spigt, M., Gidding, L. G., Blanco, R., & Dinant, G. (2015) · Tropical Doctor · doi:10.1177/0049475515581126 · Cited by 2
“The degree to which clinical actions specific for smear-negative TB are performed is largely unknown, owing to its relatively low public health priority(3) and there is an assumption that the prognosis for smearnegative cases is better than for smear-positive cases.(4,5) We hypothesised those clinical measures related…”
BackgroundLa diabetes tipo 2 y la tuberculosis en México: la confluencia de dos retos para el sistema de salud
Elías-López, D., Melgarejo-Hernández, M. A., & Aguilar-Salinas, C. A. (2012) · Acta Médica Grupo Ángeles · Cited by 2
Vitamin D und Infektanfälligkeit
Zittermann, A., Pilz, S., & März, W. (2015) · Aktuelle Ernährungsmedizin · doi:10.1055/s-0035-1552694 · Cited by 2
Gebreegziabher, S. B., Bjune, G. A., & Yimer, S. A. (2017) · Infectious Diseases of Poverty · doi:10.1186/s40249-017-0371-6 · Cited by 2
“Undiagnosed cases remained infectious throughout the year [20], and serve as a continuous pool for generating”
BackgroundZerdo, Z., Tsalla, T., Shibru, T., & Trifa, Z. M. (2015) · International Journal of Sciences: Basic and Applied Research · Cited by 2
Depresión en pacientes con tuberculosis en una región del Perú: Un estudio transversal
Bonilla-Asalde, C. A., Rivera-Lozada, I. C., & Rivera‐Lozada, O. (2020) · Revista de Investigación de la Universidad Norbert Wiener · doi:10.37768/unw.rinv.08.01.004 · Cited by 2
“J Abnorm Psychol 2012; 119(4): 791-803.”
Serum vitamin D level in newly detected tuberculosis-a case control study
Thambi, N., Vadakkedath, A., Shafeekk, M., Kottarath, M., Mavila, R., & Veetil, P. K. (2022) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20220982 · Cited by 2
(2019) · Asia-Pacific Biotech News · doi:10.1142/s021903031900017x · Cited by 2
Case Report: Tuberculosis Autoregression after Minimal Treatment and Review of the Literature
Walter, C., Acuña-Villaorduña, C., Hochberg, N. S., & Sinha, P. (2022) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.21-0839 · Cited by 2
Hanina, H., Fairuz, F., Dewi, H., Lipinwati, L., & Iskandar, M. M. (2023) · Medical Dedication (medic) Jurnal Pengabdian kepada Masyarakat FKIK UNJA · doi:10.22437/medicaldedication.v6i2.28780 · Cited by 2
Woldeyes, B. G. (2016) · Unisa Institutional Repository (University of South Africa) · Cited by 4
Tanner, R. (2015) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-o110zovob · Cited by 4
Identification of Anti-tubercular Compounds in Marine Organisms from Aotearoa
Dasyam, N. (2014) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.17008141 · Cited by 2
The Titanic question in TB control: Should we worry about the bummock?
Fortune, S. M. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2403321121 · Cited by 2
Estrategias para mejorar la adherencia al tratamiento de la tuberculosis
Discacciati, V. R. (2025) · Evidencia actualizacion en la práctica ambulatoria · doi:10.51987/evidencia.v28i3.7168 · Cited by 2
Kowada, A. (2024) · Epidemiology and Infection · doi:10.1017/s0950268823002030 · Cited by 2
“Multi-drug-resistant tuberculosis (MDR-TB) rate, TB recurrence rate, the mortality of untreated TB, and the annual risk of TB reactivation were obtained from Japanese TB statistics and the literature [2, 27, 28].”
MethodPreventing tuberculosis with community‐based care in an HIV‐endemic setting: a modelling analysis
Ross, J. M., Greene, C., Broshkevitch, C. J., Dowdy, D. W., van Heerden, A. C., Heitner, J., Rao, D. W., Roberts, D. A., Shapiro, A. E., Zabinsky, Z. B., et al. (2024) · Journal of the International AIDS Society · doi:10.1002/jia2.26272 · Cited by 1
“For simplicity, LTBI clearance [24] and recovery from active TB without treatment [25] are incorporated into rates of progression to active TB and recovery, respectively.”
Kiss, G., Moutari, S., Mctaggart, C., Patterson, L., Kee, F., & Lamrock, F. (2024) · Quantitative Biology · doi:10.1002/qub2.50 · Cited by 1
“However, the case fatality rate can be significantly higher even in vaccine preventable diseases [33].”
Nugroho, N. B., ETIKA, B., Rahayu, S. T., Wibowo, A., & Siska, E. (2025) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2025v17i2.52759 · Cited by 1
Sajjad, U., Niazi, K. K., Beamer, G., & Gürcan, M. N. (2025) · SPIE Medical Imaging: Digital and Computational Pathology · doi:10.1117/12.3047288 · Cited by 1
“Among those infected with M.tb, individuals who are susceptible develop active pulmonary TB, a disease that carries a mortality rate of 40-70% if left untreated [2].”
Data-driven targets for reducing the global burden of TB
Horsburgh, C. R., Jenkins, H. E., Martínez, L., & White, L. F. (2025) · IJTLD OPEN · doi:10.5588/ijtldopen.25.0014 · Cited by 1
Nuwematsiko, R., Kiwanuka, N., Atuyambe, L. M., Wobusobozi, I., Kasiita, V., Kagongwe, S., Ssenyonga, R., Kalyango, J. N., Nankabirwa, V., & Buregyeya, E. (2025) · JMIR Research Protocols · doi:10.2196/70325 · Cited by 3
“Patients with untreated TB remain infectious and can transmit TB to others, while failure to initiate treatment contributes to increased morbidity and mortality [23-26].”
Shalaby, M. M., Samir, R., Ibrahim, K. A., Elkhamissy, T. R., & Rammadan, M. A. (2025) · BMC Microbiology · doi:10.1186/s12866-025-04361-1 · Cited by 1
“…(a 4 to 6 month protocol) with the administration of multiple agents along with other influencing factors such as poverty accompanied by its consequent malnutrition in developing countries, and immunocompromised populations such as those suffering from HIV infection, diabetes, and smoking [5–7].”
Nuwematsiko, R., Atuyambe, L. M., Kasiita, V., Kiwanuka, N., Musiimenta, A., Rutebemberwa, E., & Buregyeya, E. (2025) · PLOS Global Public Health · doi:10.1371/journal.pgph.0004808 · Cited by 1
“Pre-diagnosis and pre-treatment loss of patients facilitates continued spread of TB in the community, poor treatment outcomes for persons with TB and death [4–8].”
New Tuberculosis Drugs and the Role of Pharmacovigilance: Issues in Resource-Limited Countries
Tiemersma, E. W., van den Hof, S., & Kimerling, M. (2025) · Springer eBooks · doi:10.1007/978-981-96-6154-1_10 · Cited by 1
Self-citationEnvironmental Contamination and Distribution of Tuberculosis in Romania
Peptenatu, D., Băloi, A., Andronic, O., Gruia, A. K., Grecu, A., Munteanu, I., Diaconu, D. C., Vlăsceanu, S. G., Drăghici, C. C., & Mahler, B. (2025) · The handbook of environmental chemistry · doi:10.1007/698_2025_1243 · Cited by 1
Gaeddert, M., Jaganath, D., Nguyen, H. T., Civan, A., Nabeta, P., Trollip, A., Castro, R., Nakabuye, M., Nsereko, M., Oumo, E. A., et al. (2025) · BMC Health Services Research · doi:10.1186/s12913-025-13546-3 · Cited by 1
Zhu, X., Lv, S.-X., Li, W., Li, R., Liu, X., & Wang, G. (2025) · Diagnostics · doi:10.3390/diagnostics15222931 · Cited by 1
“Timely diagnosis of ATBL is crucial, as untreated or delayed treatment is associated with high morbidity and mortality [3].”
Moharrum, S. A., Bilal, N. E., & Mhmoud, N. A. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-12256-9 · Cited by 1
“The risk of developing active tuberculosis is highest within the first two years after initial infection, estimated at approximately 5%, and declines substantially thereafter [5].”
Song, H.-W., Lin, Y., Wan, T.-E., Zhang, C.-F., & Pan, J. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1696952 · Cited by 1
Doran, J. W. G., Mujuni, D., Gallagher, K., Yates, C. A., & Bowness, R. (2026) · Bulletin of Mathematical Biology · doi:10.1007/s11538-026-01734-z · Cited by 1
McKenna, L., Frick, M. W., Guizado, V. A. A., Davies, G., Furin, J. J., Guglielmetti, L., Heinrich, N., Low, M., Mahmoud, M., Mave, V., et al. (2026) · Clinical Infectious Diseases · doi:10.1093/cid/ciag175 · Cited by 1
Sun, Y., Zhang, H., Liu, Y., Zhao, J., Li, N., Jing, J., & Li, P. (2026) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2026.108687 · Cited by 1
Brianwong, C. J., Cherotin, D., Ssekiswa, L., Jjuuko, R. K., Nahirya, P. N., Mugume, A., & Kiragga, D. (2026) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361261456596 · Cited by 1
Fauzi, I. S., Nuraini, N., Zahra, A., Selviana, V., Oktavia, F. Z. F., & Lestari, B. W. (2026) · Acta Tropica · doi:10.1016/j.actatropica.2026.108183 · Cited by 1
Khoda, P., Sarkar, T., Meena, O. P., & Prasad, S. N. (2026) · Chaos An Interdisciplinary Journal of Nonlinear Science · doi:10.1063/5.0332974 · Cited by 1
Novel near-point-of-care TB molecular tests: navigating the repercussions of sensitivity tradeoffs
Kendall, E. A. (2026) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.25.0793 · Cited by 3
Tuberculosis y vitamina D: una relación intrigante
Ramos, C. F. R., Montilla, J. F. S., Correa, S., Torres-Restrepo, J. M., Ramírez-Méndez, D. A., Rivera-Marín, J. D., Tovar, A. P., & Lastra-González, G. (2019) · Revista Colombiana de Endocrinología Diabetes & Metabolismo · doi:10.53853/encr.6.2.487 · Cited by 1
Lautre, H. K., Singh, R., Patil, K., Hadda, T. B., Bose, P., Kulshrestha, M. K., Prasad, C., Pillai, A. K., & Kalpana, B. (2014) · Cited by 1
Targeting Immune-Evasion Mechanisms as a Possible New Approach in the Fight against Tuberculosis
Nisini, R. (2016) · Immunological Disorders and Immunotherapy · doi:10.35248/2593-8509.16.1.101 · Cited by 1
Zuur, M. A., van Asselt, A. D. I., Boveneind-Vrubleuskaya, N. V., Aleksa, A., Postma, M. J., & Alffenaar, J. W. C. (2018) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.17.0523 · Cited by 1
Jeon, A. B., Basaraba, R. J., Borlee, B., Gustafson, D., Jackson, M., Melander, C., & Obregón-Henao, A. (2017) · Digital Collections of Colorado (Colorado State University) · doi:10.25675/3.020311 · Cited by 1
Carga de enfermedad por tuberculosis en el municipio de Pereira 2010 -2015
Correa, M. D. P. C., Forero, D. P. G., & Martínez, Y. P. (2019) · Gerencia y Políticas de Salud · doi:10.11144/javeriana.rgps18-37.cetm · Cited by 1
Chemotherapy Including Drug-Resistant Therapy
Davies, G. (2014) · CRC Press eBooks · doi:10.1201/b16604-14 · Cited by 1
Oren, E., & McDermid, J. M. (2017) · Springer eBooks · doi:10.1007/978-3-319-43739-2_17 · Cited by 1
Dowdy, D. W., Chaisson, R. E., & Churchyard, G. (2015) · doi:10.1093/med/9780199661756.003.0214 · Cited by 1
Phillips, P. P. J., & Glidden, D. V. (2022) · Springer eBooks · doi:10.1007/978-3-319-52636-2_98 · Cited by 2
Variance-based sensitivity analysis of tuberculosis transmission models
Sumner, T., & White, R. G. (2022) · Journal of The Royal Society Interface · doi:10.1098/rsif.2022.0413 · Cited by 1
Fanta, A., & Aregahegn, D. (2023) · International Archives of Nursing and Health Care · doi:10.23937/2469-5823/1510180 · Cited by 1
Yamamoto, N. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824411-1.00004-1 · Cited by 2
Mulholland, G. E., Herce, M. E., Okech, B. A., Jeremiah, K., Bahemuka, U. M., Kwena, Z., Nanyonjo, G., Seeley, J., Pettifor, A. E., Emch, M., et al. (2023) · PLOS Global Public Health · doi:10.1371/journal.pgph.0002259 · Cited by 1
Protez Eklem Enfeksiyonlarında Mycobacterium tuberculosis'in Yeri
Mehmet, K. U. R. T., Alkan, S., ÖNDER, T., & Gürbüz, E. (2023) · Phoenix Medical Journal · doi:10.38175/phnx.1251925 · Cited by 1
Faktor-Faktor Yang Memengaruhi Kepatuhan Pengobatan Pada Pasien TB
Ryansyah, I. C., Martilova, S., Putri, K., & Sinaga, E. S. (2023) · CoMPHI Journal Community Medicine and Public Health of Indonesia Journal · doi:10.37148/comphijournal.v3i3.122 · Cited by 1
Coeliac lymph node abscess: A case report of a rare manifestation of extrapulmonary tuberculosis
Goonetilleke, A., NANDASENA, M. S., Fernandopulle, N., & Matthias, A. T. (2024) · SAGE Open Medical Case Reports · doi:10.1177/2050313x241229640 · Cited by 1
Drug-resistant tuberculosis is a global cause of concern
Pedersen, O. S., Rudolf, F., Johansen, I. S., Andersen, Å. B., Lillebæk, T., Wejse, C. M., & Dahl, V. N. (2024) · Ugeskrift for Læger · doi:10.61409/v11230698 · Cited by 1
Lambert, C. J., Clarke, E., Patel, D., Laurentius, L. B., Gale, B. K., Sant, H. J., & Porter, M. D. (2024) · Analytical Methods · doi:10.1039/d4ay00772g · Cited by 1
Enhanced Tuberculosis Detection Using Deep Neural Network on Microscopic Images
Gupta, S., Jindal, R., Biji, C. L., & Dheeba, J. (2025) · Lecture notes in networks and systems · doi:10.1007/978-981-96-2697-7_12 · Cited by 2
Liu, X., Zhang, Y., Zheng, L., Zhang, N., Wang, Z., Chen, X., & Gu, B. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120565 · Cited by 1
Peter, O. J., Butt, A. I. K., Ahmad, S. S. S., & Mukahal, F. H. H. A. (2026) · AIMS Mathematics · doi:10.3934/math.2026788 · Cited by 1
Diagnostic Challenge of Tuberculosis Heterogeneity
Nemes, E., Meermeier, E. W., Scriba, T. J., Walzl, G., Malherbe, S. T., & Lewinsohn, D. M. (2018) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0038-1660471 · Cited by 1
Pseudospectral Method based Optimal Control of Tuberculosis Model
Salik, M., Banerjee, A., & Nabi, M. U. (2020) · Mediterranean Conference on Control and Automation (MED) · doi:10.1109/med48518.2020.9183257 · Cited by 1
“In the absence of treatment, the fatality rate from TB is Brobdingnagian [7].”
BackgroundTuberculosis: new era for diagnosis and surveillance using whole-genome sequencing-based approaches
Macedo, A. R. F. (2019) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · Cited by 2
Shoe Leather Infectious Disease Modeling?
Murray, M. B. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa604 · Cited by 1
Heyd, A. (2020) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3-hjbs-tg84 · Cited by 1
Tuberculosis: Nutritional management
Sinha, P., & Cegielski, J. P. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821848-8.00093-7 · Cited by 1
Do no harm - re-evaluating the risks of overtreatment in community-wide tuberculosis screeningPreprint
Houben, R. M. G. J., Veeken, L. D., Schwalb, A., Grint, D. J., Wasserman, S. A., van Crevel, R., & Horton, K. C. (2025) · medRxiv · doi:10.1101/2025.09.18.25335917 · Cited by 3
“(34,35) However, this does not negate the net benefit of providing treatment, which appears to vastly outweigh the harm.”
Melsew, Y. A., Ragonnet, R., Cheng, A. C., McBryde, E. S., & Trauer, J. M. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.26.173104 · Cited by 1
“004 [42] Average duration of infectiousness, years D 3 2-4 [43] TB-related mortality among Superspreaders, proportion μI2 0.”
BackgroundBozarth, A. L., & Salkind, A. R. (2013) · Hospital Medicine Clinics · doi:10.1016/j.ehmc.2013.07.003
Lozada, I., & Matias, M. (2013) · CORE Scholar (Wright State University) · Cited by 2
Idh, J. (2012) · DiVA (Linkoping University) · Cited by 3
Molecular detection and characterization of drug-resistant Mycobacterium tuberculosis
Engström, A. (2013) · Figshare
Impact of Mycobacterium tuberculosis and HIV-1 on innate immune mechanisms
Mazurek, J. (2012) · Figshare
Prognostic factors in tuberculosis related mortalities in hospitalized patients
Kumar, A., Haq, G., Saifuddin, F., Ghazal, S., & Rizvi, N. A. (2012) · European Respiratory Journal
Tuberculosis burden in Vietnam: What have we gained from the first national prevalence survey?
Nguyen, B. H. (2013) · UvA-DARE (University of Amsterdam)
THE ENGINE AND THE REAPER: INDUSTRIALIZATION AND MORTALITY IN EARLY MODERN JAPAN
Tang, J. P. (2015) · Institutional Repositories DataBase (IRDB)
Fortuna, E. G. (2012) · Americanae (AECID Library)
Update on Extensively Drug-resistant Tuberculosis
Lalloo, U., Pillay, S., Mngqibisa, R., & Ambaram, A. (2014) · Clinical Pulmonary Medicine · doi:10.1097/cpm.0000000000000058
“We believe that the current survival with XDR-TB approaches that estimated from the natural history of TB without anti-TB treatment.(47) In summary, factors associated with high mortality include the number of drugs the MTB is resistant, HIV (immune status), low socioeconomic status, delay in diagnosis, and adherence…”
Tuberculosis: Current strategies to control MDR
Saroshe, S., & Gedam, D. D. S. (2014) · International Journal of Medical Research and Review · doi:10.17511/ijmrr.2014.001
Pharmacometric Models to Improve Treatment of Tuberculosis
Svensson, E. M. (2016) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Antibiotic resistance among the AIDS-immunocompromised
DeNegre, A. A. (2016) · doi:10.7282/t3r49st0
Plasma indoleamine 2,3-dioxygenase activity, a potential biomarker for tuberculosis
Adu-Gyamfi, C. G. (2016)
A Review on Immunological Diagnosis Methods of Tuberculosis Infection
Jafari, M., & Mansouri, R. (2017) · DOAJ (DOAJ: Directory of Open Access Journals)
Diagnostic evaluation of smear negative tuberculosis in a resource poor setting
Mala (2017) · Research Publications (Maastricht University) · doi:10.26481/dis.20170322gom
“The degree to which clinical actions specific for smear-negative TB are performed is largely unknown, owing to its relatively low public health priority [3] and there is an assumption that the prognosis for smear-negative cases is better than for smearpositive cases [4, 5].”
BackgroundDuran, E. M. D., & Ramírez, C. A. V. (2016) · Repositorio Digital de Ciencia y Cultura de El Salvador (Consorcio de Bibliotecas Universitarias de El Salvador)
Desenvolvimento de nanoblenda magnética a base de ácidos clorogênico e labdânico
Bezerra, M. G. F. (2015) · doi:10.26512/2015.07.d.19126
Optimal Use of New and Existing Drugs for Tuberculosis Control
Kunkel, A. (2016) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
OBSOLETE: Tuberculosis Epidemiology
Sotgiu, G. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.98778-6
Genome scale tracking of Mycobacterium tuberculosis MazF toxin targets
Greendyk, J. R. (2017) · doi:10.7282/t3k077d9 · Cited by 1
“Around 70% of patients with active TB will die if the infection is left untreated (Tiemersma et al., 2011).”
BackgroundAbbadi, B. L. (2018) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
OPTIMIZATION IN INFECTIOUS DISEASE CONTROL AND PREVENTION
Suen, S. (2018) · Wiley eBooks · doi:10.1002/9781118960158.ch1
Pacheco, S. M. C. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.42.2018.tde-09042018-171215
Alireza, S. (2017) · University of Malaya Students Repository
Maximising value for money of tuberculosis investment in the Philippines
Garfin, A. M. C., Gaviola, D. M. G., Camacho, E. E., Nalda, R., Mantala, M. J., Magboo, S., Yadav, R. B., Doan, T. N., Trauer, J. M., Ragonnet, R. R., et al. (2017)
Zheng, S., & Thien, S.-Y. (2018) · International Journal of Mycobacteriology · doi:10.4103/ijmy.ijmy_103_18
“International Journal of Mycobacteriology ¦ Volume 7 ¦ Issue 3 ¦ July‐September 2018 287 based on prechemotherapy data.[11] Our case demonstrated an interesting intricate balance between the tubercle bacilli and the innate host immune response pretuberculous chemotherapy.”
BackgroundSíntese de biblioteca de derivados quinoidais e quinoxalínicos visando à atividade biológica
Franco, M. S. F. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.60.2018.tde-22052018-155948
Byng-Maddick, R. (2018) · UCL Discovery (University College London)
Zineldin, M. A. I., Oaf, F., Risk, E., Elshabrawi, A. E., Elghonemy, K.-E., & Abdel-Khalek, A.-F. (2018) · Al-Azhar Assiut Medical Journal · doi:10.4103/azmj.azmj_11_18
Ragonnet, R. R. (2018) · Minerva Access (University of Melbourne)
Metadata
- Authors
- Tiemersma, E. W., van der Werf, M. J., Borgdorff, M. W., Williams, B. G., & Nagelkerke, N. J. D.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- GGD Amsterdam (NL)
- Stellenbosch University (ZA)
- United Arab Emirates University (AE)
- Corresponding author
- Tiemersma, Edine W.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-04-04
- Volume
- 6
- Issue
- 4
- Pages
- e17601
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3070694
- OpenAlex
- W2138041013
- Cited by
- 583
- References
- 136
- Citations by year
- 2026: 33 · 2025: 53 · 2024: 46 · 2023: 48 · 2022: 40 · 2021: 36 · 2020: 38 · 2019: 39 · 2018: 43 · 2017: 42 · 2016: 35 · 2015: 43 · 2014: 39 · 2013: 31 · 2012: 10
- FWCI
- 3.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UvA-DARE (University of Amsterdam) (publishedVersion, other-oa)
- Pure Amsterdam UMC (publishedVersion)
- UvA-DARE (University of Amsterdam) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- SUNScholar (Stellenbosch University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- World Health Organization
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › HIV, TB, and STIs Epidemiology
- Keywords
- case fatality, disease duration, HIV-negative patients, smear-positive tuberculosis, smear-negative tuberculosis, culture-positive tuberculosis, tuberculosis prognosis
- MeSH terms
- Humans, Time Factors, Tuberculosis, Pulmonary, Survival Analysis, HIV Seronegativity, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.